Skip to main content
Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery 4/2023

07.06.2023 | Original Article

A Clinicopathological Study of OSMF to Evaluate the Response After Treatment with Intralesional Steroid Versus Intralesional Steroid Plus Hyaluronidase

verfasst von: Gaurav Kumar Goldar, Hitendra Prakash Singh, Malti Kumari Maurya, Sunil Kumar, Manish Chandra, Abhishek Bahadur Singh, Veerendra Verma, Anupam Mishra

Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Oral submucous fibrosis (OSMF) is a chronic debilitating and a well-recognized potentially malignant condition of the oral cavity, sometimes involving oropharynx associated with trismus and burning sensation. Apart from medical management and counselling, local injection of hyaluronidase mixed with triamcinolone acetonide has been used at our centre for the last 20 years with satisfactory clinical results and without any significant side effects. The problem with the treatment was that the doses and duration of treatment has not been standardized. Therefore, in this study, authors aim to evaluate and compare the efficacy of Triamcinolone alone versus Triamcinolone acetonide plus Hyaluronidase at weekly interval and improvement in Clinical and Histopathological staging of disease after 6 weeks of treatment. This study was conducted in Department of Otorhinolaryngology & Head Neck Surgery, with a total sample of 80 participants divided into two Groups, group A received Inj. Triamcinolone acetonide and group B received Inj. Triamcinolone Acetonide and Hyaluronidase 1500 IU at weekly interval. Pre-treatment and post-treatment clinical and histopathological profile of the patients were recorded and analyzed using SPSS 16 software. According to pre-treatment status, the proportion of clinical grades I, II and III were found in proportion 12.5%, 18.8% and 15.0% respectively. No significant difference was found in proportion of various grades between the groups (p = 0.388). At post treatment, the grading was reduced with changed proportion of grades I, II and III cases as 33.8%, 41.3% and 7.5% respectively. There was no significant difference in proportion of various grades between the groups (p = 0.681). Further, the intragroup comparison showed significant improvement Pre to post in group A (p = 0.002), Group B (p < 0.001) and overall, as well (p < 0.001). The inj. Triamcinolone acetonide and Inj. Hyaluronidase showed a better improvement on post treatment histopathological grading although the difference between the two groups was not significant statistically.
Literatur
1.
Zurück zum Zitat Borle RM, Borle SR (1991) Management of oral submucous fibrosis: a conservative approach. J Oral MaxillofacSurg 49(8):788–791CrossRef Borle RM, Borle SR (1991) Management of oral submucous fibrosis: a conservative approach. J Oral MaxillofacSurg 49(8):788–791CrossRef
2.
Zurück zum Zitat Shafer WG, Hine MK, Levy BM (1983) A Textbook of Oral Pathology. 4th ed. Ch. 2. Philadelphia: W.B. Saunders Company; Benign and malignant tumour of the oral cavity; p. 109 Shafer WG, Hine MK, Levy BM (1983) A Textbook of Oral Pathology. 4th ed. Ch. 2. Philadelphia: W.B. Saunders Company; Benign and malignant tumour of the oral cavity; p. 109
3.
4.
Zurück zum Zitat Pindborg JJ, Bhonsle RB, Murti PR, Gupta PC, Daftary DK, Mehta FS et al (1980) Incidence and early forms of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol 50:40–44CrossRefPubMed Pindborg JJ, Bhonsle RB, Murti PR, Gupta PC, Daftary DK, Mehta FS et al (1980) Incidence and early forms of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol 50:40–44CrossRefPubMed
5.
Zurück zum Zitat Gupta D, Sharma SC (1988) Oral submucous fibrosis- -a new treatment regimen. J Oral MaxillofacSurg 46(10):830–833CrossRef Gupta D, Sharma SC (1988) Oral submucous fibrosis- -a new treatment regimen. J Oral MaxillofacSurg 46(10):830–833CrossRef
6.
Zurück zum Zitat Le PV, Gornitsky M, Domanowski G (1996) Oral stent as treatment adjunct for oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral RadiolEndod 81(2):148–150CrossRef Le PV, Gornitsky M, Domanowski G (1996) Oral stent as treatment adjunct for oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral RadiolEndod 81(2):148–150CrossRef
7.
Zurück zum Zitat Khan I, Agarwal P, Thangjam GS, Radhesh R, Rao SG, Kondaiah P (2011) Role of TGF-ß and BMP7 in the pathogenesis of oral submucous fibrosis. Growth Factors 29:119–127CrossRefPubMed Khan I, Agarwal P, Thangjam GS, Radhesh R, Rao SG, Kondaiah P (2011) Role of TGF-ß and BMP7 in the pathogenesis of oral submucous fibrosis. Growth Factors 29:119–127CrossRefPubMed
8.
Zurück zum Zitat Sinha SN, Jain PK (1978) Intraoral injection of hydrocortisone and placental extract in oral submucous fibrosis. Indian J Otolaryngol 30(2):103CrossRef Sinha SN, Jain PK (1978) Intraoral injection of hydrocortisone and placental extract in oral submucous fibrosis. Indian J Otolaryngol 30(2):103CrossRef
9.
Zurück zum Zitat Singh M, Niranjan HS, Mehrotra R, Sharma D, Gupta SC (2010) Efficacy of hydrocortisone acetate/hyaluronidase vs. triamcinolone acetonide/hyaluronidase in the treatment of oral submucous fibrosis. Indian J Med Res 131:665–669PubMed Singh M, Niranjan HS, Mehrotra R, Sharma D, Gupta SC (2010) Efficacy of hydrocortisone acetate/hyaluronidase vs. triamcinolone acetonide/hyaluronidase in the treatment of oral submucous fibrosis. Indian J Med Res 131:665–669PubMed
10.
Zurück zum Zitat Sinor PN, Gupta PC, Murti PR, Bhonsle RB, Daftary DK, Mehta FS, Pindborg JJ (1990) A case-control study of oral submucous fibrosis with special reference to the etiologic role of areca nut. J Oral Pathol Med 19:94–98CrossRefPubMed Sinor PN, Gupta PC, Murti PR, Bhonsle RB, Daftary DK, Mehta FS, Pindborg JJ (1990) A case-control study of oral submucous fibrosis with special reference to the etiologic role of areca nut. J Oral Pathol Med 19:94–98CrossRefPubMed
11.
Zurück zum Zitat Joshi SG (1953) Submucous fibrosis of the palate and pillars. Ind J otolaryn 4:1–4 Joshi SG (1953) Submucous fibrosis of the palate and pillars. Ind J otolaryn 4:1–4
12.
Zurück zum Zitat Reddy V, Wanjari PV, Banda NR, Reddy P (2011) Oral submucous fibrosis: correlation of clinical grading to various habit factors. Int J Dent Clin 3:21–24 Reddy V, Wanjari PV, Banda NR, Reddy P (2011) Oral submucous fibrosis: correlation of clinical grading to various habit factors. Int J Dent Clin 3:21–24
13.
Zurück zum Zitat Verma V et al (2018) Oral Submucous fibrosis-correlation between clinical findings and histopathological grading. Bengal J Otolaryngol Head Neck Surg 26:91–98Maurya MKCrossRef Verma V et al (2018) Oral Submucous fibrosis-correlation between clinical findings and histopathological grading. Bengal J Otolaryngol Head Neck Surg 26:91–98Maurya MKCrossRef
14.
Zurück zum Zitat Shiau YY, Kwan HW (1979) Submucous fibrosis in Taiwan. Oral surg. Oral med. oral pathol 47:453–457CrossRef Shiau YY, Kwan HW (1979) Submucous fibrosis in Taiwan. Oral surg. Oral med. oral pathol 47:453–457CrossRef
15.
Zurück zum Zitat Ramanathan K (1981) OSMF-An alternative hypothesis as to its causes. Med J Malaysia 36:243–245PubMed Ramanathan K (1981) OSMF-An alternative hypothesis as to its causes. Med J Malaysia 36:243–245PubMed
16.
Zurück zum Zitat McGurk M, Craig GT (1984) Oral submucous fibrosis: two cases of malignant transformation in asian immigrants to the United Kingdom. Br J Oral Maxillofac Surg 22:56–64CrossRefPubMed McGurk M, Craig GT (1984) Oral submucous fibrosis: two cases of malignant transformation in asian immigrants to the United Kingdom. Br J Oral Maxillofac Surg 22:56–64CrossRefPubMed
17.
Zurück zum Zitat Sikdar SD, Bagachi SS, Sood M (2014) Eifficacy of intralesional triamcinolone acetonide and hyaluronidase compared with that of placentral extract in the treatment of OSMF: a comparative clinical study. Int J Women Dent 1:55–59 Sikdar SD, Bagachi SS, Sood M (2014) Eifficacy of intralesional triamcinolone acetonide and hyaluronidase compared with that of placentral extract in the treatment of OSMF: a comparative clinical study. Int J Women Dent 1:55–59
18.
Zurück zum Zitat Kakar PK, Puri PK, Venkatachalam VP (1985) Oral submucous fibrosis. Treat hyalase J laryngol otol 95;55–59 Kakar PK, Puri PK, Venkatachalam VP (1985) Oral submucous fibrosis. Treat hyalase J laryngol otol 95;55–59
19.
Zurück zum Zitat Pindborg JJ, Bhonsle RB, Murti PR, Gupta PC, Daftary DK, Mehta FS et al (1980) Incidence and early forms of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol 50:40–44CrossRefPubMed Pindborg JJ, Bhonsle RB, Murti PR, Gupta PC, Daftary DK, Mehta FS et al (1980) Incidence and early forms of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol 50:40–44CrossRefPubMed
20.
Zurück zum Zitat Pindborg JJ (1972) Is submucous fibrosis a precancerous condition in the oral cavity? Int Dent J 22:474–480PubMed Pindborg JJ (1972) Is submucous fibrosis a precancerous condition in the oral cavity? Int Dent J 22:474–480PubMed
21.
Zurück zum Zitat Patel TL, Singh S (2015) Comparative evaluation of treatment of oral Submucous fibrosis with Intralesional Injections of Dexamethasone and Hyaluronidase with Triamcinolone Acetonide and Hyaluronidase. J Cont Med A Dent 3:32–34CrossRef Patel TL, Singh S (2015) Comparative evaluation of treatment of oral Submucous fibrosis with Intralesional Injections of Dexamethasone and Hyaluronidase with Triamcinolone Acetonide and Hyaluronidase. J Cont Med A Dent 3:32–34CrossRef
22.
Zurück zum Zitat Karthik PM, Sande A, Ashwini rani SR, Nayak A, Pawar R, Patil P (2015) Comparison of Mouth opening with different non-surgical treatment modalities in oral Submucous Fibrosis. Am J Drug Delivery Ther 2:72–75 Karthik PM, Sande A, Ashwini rani SR, Nayak A, Pawar R, Patil P (2015) Comparison of Mouth opening with different non-surgical treatment modalities in oral Submucous Fibrosis. Am J Drug Delivery Ther 2:72–75
Metadaten
Titel
A Clinicopathological Study of OSMF to Evaluate the Response After Treatment with Intralesional Steroid Versus Intralesional Steroid Plus Hyaluronidase
verfasst von
Gaurav Kumar Goldar
Hitendra Prakash Singh
Malti Kumari Maurya
Sunil Kumar
Manish Chandra
Abhishek Bahadur Singh
Veerendra Verma
Anupam Mishra
Publikationsdatum
07.06.2023
Verlag
Springer India
Erschienen in
Indian Journal of Otolaryngology and Head & Neck Surgery / Ausgabe 4/2023
Print ISSN: 2231-3796
Elektronische ISSN: 0973-7707
DOI
https://doi.org/10.1007/s12070-023-03930-y

Weitere Artikel der Ausgabe 4/2023

Indian Journal of Otolaryngology and Head & Neck Surgery 4/2023 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.